Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 9/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.36 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.36 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164653 | 0.86 | POLB (0.42) | L3MBTL3L3MBTL1SIGMAR1CHRM2CHRM4 | |
| SCHEMBL29588116 | 0.85 | ALDH1A1 (0.41) | L3MBTL3L3MBTL1HTR6MBTD1TP53BP1 | |
| Hydrochloric Acid SCHEMBL3953750 | 0.83 | ALDH1A1 (0.44) | L3MBTL3L3MBTL1HTR6POLB | |
| Hydrochloric Acid SCHEMBL4139677 | 0.83 | ALDH1A1 (0.44) | L3MBTL3L3MBTL1HTR6POLB | |
| SCHEMBL7492461 | 0.78 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1SIGMAR1POLBHSD17B10 | |
| SCHEMBL14809831 | 0.77 | CHRM1 (0.39) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL203949 | 0.77 | MEN1 (0.42) | L3MBTL3L3MBTL1 | |
| SCHEMBL24003728 | 0.76 | L3MBTL3 (0.44) | L3MBTL3L3MBTL1MBTD1TP53BP1L3MBTL4 | |
| SCHEMBL21078296 | 0.76 | RAB9A (0.39) | L3MBTL3L3MBTL1HTR6CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL28524461 | 0.76 | ALDH1A1 (0.44) | L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101998959-B | Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARM INC | 2013-08-28 | — | — | CN | disclosed |
| US-8088760-B2 | Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-01-03 | — | — | US | disclosed |
| CN-101998959-A | Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) | LEAD THERAPEUTICS INC | 2011-03-30 | — | — | CN | disclosed |
| EP-2247600-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Lead Therapeutics, Inc. (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009099736-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | L3MBTL3 3984/4885L3MBTL1 3345/4885HTR6 2051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.